MAR 25·AD HOC NEWS▼
Harmony Biosciences stock faces pipeline scrutiny amid Polaryx integration challenges and rare disease market shifts
Harmony Biosciences is facing scrutiny over its pipeline following the 2025 acquisition of Epygenix Therapeutics, as Polaryx Therapeutics' recent 10-K filing reveals overlapping rare disease programs with their shared backer, Mstone Partners. US investors are closely monitoring how Harmony navigates integration challenges, competitive pressures, and the need to differentiate its assets in the neurology orphan drug market. The article highlights the strategic implications of these connections for Harmony's stock performance and resource allocation.
FEB 23·Investing.com▼
Deutsche Bank cuts Harmony Biosciences stock rating on patent risk
Deutsche Bank has downgraded Harmony Biosciences (NASDAQ: HRMY) to Hold from Buy and lowered its price target due to increased patent risk for its lead drug, Wakix. A recent bench trial indicated a negative outcome for Harmony Biosciences against a generics manufacturer, potentially accelerating Wakix's loss of exclusivity. Despite the legal uncertainty, the stock appears undervalued according to InvestingPro analysis, even as shares declined following the trial's conclusion.
